You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 5, March 11, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Timing of Hypercoagulable Screens

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drs Federman and Kirsner provide an excellent review of the hypercoagulable disorders.1 Clearly, the number of these disorders are increasing by the year; however, our knowledge of what to do with the results is not quite keeping up.

In their article, they make a statement to the effect that the levels of protein C, protein S, and anti–thrombin III should not be measured at the time of an acute episode of thrombosis because the levels are decreased during an acute event. They recommend measuring levels of protein C and protein S several months down the road, which would necessitate discontinuing warfarin therapy, usually for a period of 14 days, and potentially covering with daily injections of low-molecular-weight heparin.

At my institution, the practice has been to measure the levels of protein C, protein S, and anti–thrombin III at the time of the acute event. In more than 95% of the . . . [Full Text of this Article]







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.